Comparative Pharmacology
Head-to-head clinical analysis: TAZAROTENE versus ZENATANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAZAROTENE versus ZENATANE.
TAZAROTENE vs ZENATANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tazarotene is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity, modulating gene expression involved in cell proliferation, differentiation, and inflammation.
Isotretinoin (13-cis-retinoic acid) reduces sebaceous gland size and inhibits sebum production by binding to nuclear retinoic acid receptors (RARs and RXRs), altering gene expression involved in cell differentiation and apoptosis.
Topical: Apply a pea-sized amount to affected areas once daily in the evening. For plaque psoriasis, use 0.05% or 0.1% gel or cream. For acne vulgaris, use 0.1% cream or 0.045% or 0.1% lotion.
0.5 mg/kg orally once daily, titrated up to 1 mg/kg/day based on response; maximum 2 mg/kg/day.
None Documented
None Documented
Clinical Note
moderateTazarotene + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Tazarotene."
Clinical Note
moderateTazarotene + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Tazarotene."
Clinical Note
moderateTazarotene + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Tazarotene."
Clinical Note
moderateTazarotene + Nilotinib
Terminal elimination half-life of tazarotenic acid is 7–12 hours in healthy subjects; clinically, steady-state is achieved within 14 days.
Terminal elimination half-life is 16-22 hours (mean 19 hours) in adults. Steady-state achieved in 3-5 days. Half-life may be prolonged up to 40 hours in severe renal impairment (CrCl <30 mL/min).
Primarily fecal (approximately 60%) and urinary (approximately 13%) as metabolites; unchanged drug not detected in urine.
Primarily renal excretion as unchanged drug (60-70%) and glucuronide conjugates (10-20%). Fecal elimination accounts for 10-15% via biliary secretion.
Category D/X
Category C
Retinoid
Retinoid
"The metabolism of Nilotinib can be decreased when combined with Tazarotene."